Figure 2.

Comparison of the cellular and molecular immune environment of a B cell murine lymphoma implanted in the spleen, in the brain or in the eye. (a) A20.IIA-GFP cells were implanted in immunocompetent syngeneic mice in the spleen (intrasplenic lymphoma model: ISL), in the brain (primary intracerebral lymphoma model: PCL), or in the eye (primary intraocular lymphoma model: PIOL). 21 days after injection, tumor-bearing organs were analyzed by flow cytometry for the presence of GFP⁺ tumor cells, CD3⁺ T lymphocytes, NKp46⁺ NK cells, Gr1⁺ neutrophils, CD11c⁺ dendritic cells, and CD11b⁺CD11c⁻ macrophages. Results are represented as the proportion of the different populations among total living cells (n = 10). (b) 21 days after lymphoma (gray boxes) or PBS (white boxes) injection, cells were isolated from appropriate tissues and stimulated for 36 h with anti-CD3/CD28-coated Dynal beads. Secretion of IL-2, IFNγ, GM-CSF, IL-4, IL-10, and IL-17 in the culture supernatant was evaluated by cytokine bead arrays (BD Biosciences) (n = 10). Animal studies were conformed to European Union guidelines and were approved by the Charles Darwin Ethics Committee in Animal Experiment, Paris, France.